News | July 06, 2022
Wacker to expand mRNA-based actives capacity at Halle, Germany
Company is investing more than €100 million in the expansion of the Halle site
Company is investing more than €100 million in the expansion of the Halle site
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
The Congress was held on June, 20-21, 2022 in Berlin, Germany
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Brings 25 years of global operations and supply chain experience to Piramal
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Subscribe To Our Newsletter & Stay Updated
